For testing the in vivo efficacy of B002T‐LP004, four cell line‐derived xenograft (CDX) mouse models were selected for testing the in vivo efficacy of B002T‐LP004, including the HCC1954/CB17SCID immunodeficient murine HER2 high‐expression human breast cancer model, the SNU‐5/CB17SCID immunodeficient murine HER2 low‐expression human gastric cancer model, the JIMT/CB17SCID immunodeficient murine human breast cancer model, and the MC38‐hHER2/C57 immunocompetent murine colorectal cancer model. This evidence concerns the gene ERBB2 and breast carcinoma.